Gene therapy has evolved as a favorable treatment option for several diseases (primarily the ones that currently have no cure) such as viral infections, cancers, and inherited disorders. Gene therapy and genetically modified therapy involve the introduction of a therapeutic DNA (the gene of interest) in the body of the patient. The process of gene transfer into the cells is achieved by the application of vectors. In the last few years, several viral and nonviral (plasmid DNAs) have been standardized and optimized for this purpose.
The major factors that fuel the growth of the viral vectors and plasmid DNA manufacturing market include rise in number of candidates of gene therapy combined with their swift development through the numerous phases of clinical progression, ability of the vectors to express therapeutic genes efficiently, and nonpathogenic nature of vectors.
However, possible insertional mutagenesis and high cost of gene therapies impede the market growth. Technological advancements to alleviate the challenges caused by the traditional methods of vector production provide broad range of opportunities for the manufacturers in this market.
The global viral vector and plasmid DNA manufacturing market is segmented on the basis of product, application, and geography. Based on product, the market is divided into plasmid DNA, viral vectors, and nonviral vectors. Applications covered in this study include cancers, inherited disorders, viral infections, and others. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key companies profiled in this report include Spark Therapeutics, Inc., Genzyme Corporation, Aldevron, Kaneka Eurogentec S.A., Biovian, Brammer Bio, Cobra Biologics, FinVector Vision Therapies, Oxford Gene Technology, and Vigene Biosciences Inc.
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market by type assists to understand the regional trends.
- Key players and their strategies have been analyzed to understand the competitive outlook of the market.
Viral Vectors And Plasmid DNA Manufacturing Market Key Segments:
- Plasmid DNA
- Viral Vectors
- Nonviral Vectors
- Inherited Disorders
- Viral Infections
- North America
- Rest of Europe
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- Rest of LAMEA